RESEARCH PEPTIDE FUNDAMENTALS / ROUTE MATRIX
Three Peptides, Three Very Different Delivery Records
How BPC-157, CJC-1295, and semaglutide actually compare on what route has been studied, what bioavailability looks like, and what's still just marketing.
The short version
This page lines up BPC-157, CJC-1295, and semaglutide on the dimensions that matter for a delivery-route comparison: what route the human (or best-available animal) pharmacokinetic data actually covers, what bioavailability looks like where it's been measured, regulatory status, and the single biggest caution for each. The short version: only semaglutide has a genuinely engineered, separately measured oral route. BPC-157's only human data point is an intravenous safety pilot; CJC-1295's entire human record is subcutaneous. For all three, "sublingual" and "transdermal" are unverified in the published literature. None of this is medical advice, and no dose is recommended anywhere on this page.
The comparison matrix
| Dimension | BPC-157 | CJC-1295 | Semaglutide |
|---|---|---|---|
| Peptide class | Gastric-derived cytoprotective pentadecapeptide | GHRH analog (DAC and no-DAC variants) | GLP-1 receptor agonist |
| Route(s) with published PK data | Intramuscular (rats, dogs) [3]; intravenous (2-person human pilot) [1] | Subcutaneous only (human) [9][10] | Subcutaneous injection AND oral tablet, both human [15] |
| Bioavailability where measured | ~14-19% IM (rats), ~45-51% IM (dogs) [3]; not measured for oral/sublingual in humans | Not reported as a bioavailability figure; half-life 5.8-8.1 days after SC dosing [9] | Oral: ~0.4-1% with SNAC enhancer [15]; injectable: engineered for ~1-week half-life |
| Regulatory status | Not FDA-approved; excluded from 503A compounding bulks (2023) | Not FDA-approved; immunogenicity concerns flagged in 2024 FDA review | FDA-approved, multiple indications, both injectable and oral [15] |
| Key caution | Human evidence is extremely thin; mostly one research group [2] | Sustained IGF-1 elevation is a theoretical cancer concern; discontinued original DAC program | GI intolerance during titration; oral tablet needs strict fasted dosing [15] |
Route: what's actually been measured
The honest headline is that two of these three compounds have never had a human oral, sublingual, or transdermal pharmacokinetic study published at all. BPC-157's only formal PK data comes from intramuscular dosing in rats and dogs, where it directly outperformed intragastric (oral) delivery in the same rat ulcer-healing experiments [3][5]; its only human data point is an intravenous safety pilot in two adults [1]. CJC-1295's human pharmacology is subcutaneous-only, full stop [9][10]. Semaglutide is the exception: it has a real oral tablet, built around a specific absorption-enhancer chemistry, with its own measured, low bioavailability and its own dosing rules [15].
Bioavailability: the numbers that exist
Where a bioavailability number does exist, it tells a humbling story about how hard oral peptide delivery actually is. BPC-157's intramuscular bioavailability was measured at roughly 14-19% in rats and 45-51% in dogs — and that's the injectable route, not oral [3]. Semaglutide's oral tablet, despite a dedicated absorption-enhancer technology and years of formulation work, still only reaches about 0.4-1% bioavailability [15]. No comparable number exists for CJC-1295 by any route other than subcutaneous, and no oral or sublingual bioavailability figure exists in the published literature for either BPC-157 or CJC-1295 in humans.
Regulatory and evidence status
Semaglutide is the only FDA-approved compound of the three, across several indications, and in both its injectable and oral forms [15]. BPC-157 has no FDA approval in any form and was specifically excluded from the 503A pharmacy-compounding bulks list in 2023. CJC-1295 likewise has no FDA approval, and 2024 FDA briefing materials flagged immunogenicity concerns when reviewing it for that same compounding pathway. All three are sold by research-chemical suppliers outside any of these regulatory pathways, in forms — oral, sublingual, transdermal — that in two of the three cases have no published data behind them at all.
Key caution
For BPC-157 it's the sheer thinness of human evidence — a two-person IV pilot and a handful of other small studies, atop a preclinical record dominated by one research group [1][2]. For CJC-1295 it's the combination of sustained IGF-1 elevation, a theoretical cancer concern, and a discontinued original development program. For semaglutide, the caution isn't about whether it works — it clearly does, across multiple large trials — but about gastrointestinal tolerability during dose escalation, and about the oral tablet's unforgiving fasted-dosing requirement, where a normal breakfast can erase most of the already-small absorbed dose [15].